Browse News
Filter News
Found 543,475 articles
-
Stanford University researchers kicked off the annual meeting of the American College of Cardiology (ACC) with a very large study of more than 400,000 patients in a trial sponsored by Apple.
-
Within the non-medical community, there is a tendency to just refer to dementia and Alzheimer’s interchangeably, but the Alzheimer’s Disease-Related Dementias Summit 2019 emphasized that physicians need to make the distinction for best patient care.
-
ACC Roundup: Less Aspirin to Prevent Heart Attacks, Bristol-Myers & Pfizer, Apple Watch and More
3/18/2019
The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting. -
March is Women’s History Month, with March 8 designated as International Women’s Day. Let’s take a look at 10 pioneers, some still alive, and some who are no longer with us, who are pioneers in the field of biotechnology.
-
It’s a busy week for the U.S. Food and Drug Administration (FDA) with quite a number of pending drug approvals, several of which were delayed for a variety of reasons. Here’s a look.
-
Are you familiar with the medical writing profession? If not, you could be missing out on one of the most flexible and rewarding careers in life sciences.
-
The stock is up more than 100 percent after the company announced positive results from a Phase IIb study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis.
-
Aerpio said the Phase IIb asset did show some positive data in a number of pre-specified secondary endpoints, including changes in Urine Albumin-Creatinine Ratio, a measure of kidney function, and in intraocular pressure.
-
Alcon said the acquisition of PowerVision demonstrates its commitment to bringing advanced technology intraocular lenses to cataract patients across the globe.
-
The latest financing round will boost the study of KarXT, Karuna’s lead product candidate, which is currently in Phase II development as a potential treatment for acute psychosis in patients with schizophrenia.
-
QxMD Adds Mobile-First Continuing Medical Education (CME) Programming to Its HCP Content Engagement Platform
3/18/2019
In addition to earning CME credits for literature searches, busy healthcare professionals (HCPs) can now also acquire credits through mobile learning courses in a matter of minutes each day.
-
SpinalCyte to Present at China Focus @ Europe Vienna
3/18/2019
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced that Pete O’Heeron, SpinalCyte’s Chief Executive Officer, will present at the China Focus @ Europe Vienna on Wednesday, March 27, 2019 at 3:00 PM CET in Vienna, Austria.
-
National concussion guidelines announced for high performance sport in Canada
3/18/2019
Canada's high performance sport community has announced national sport-related concussion guidelines designed to protect its national and next generation athletes.
-
Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter
3/18/2019
Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level.
-
Galderma Announces U.S. Collaboration with Nespresso®
3/18/2019
Galderma Laboratories, L.P., a global leader focused on meeting the world's increasing skin health needs, recently announced a new collaboration with Nespresso, the worldwide pioneer and reference in high-quality, portioned coffee.
-
Transgene Secures a €20 Million Revolving Credit Facility with Natixis
3/18/2019
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that it has secured a €20 million revolving credit facility with Natixis, the French Corporate and Investment bank.
-
Allergy Therapeutics announces top-line Phase III results from its B301 clinical trial
3/18/2019
Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced top-line results from the Phase III clinical trial B301of its new adjuvanted birch allergoid product
-
Elite and Club Runners to Race for $20,000 in Prize Money at the 29th Annual Lawyers Have Heart Race
3/18/2019
For the second year in a row, runners will race for $20,000 in prize money at the Lawyers Have Heart Race. Lawyers Have Heart is a premier athletic philanthropic event led by the greater DC legal community and has raised more than $13 million to benefit the American Heart Association.
-
Arix co-leads $63 million Series B investment round for Imara
3/18/2019
Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. (“Imara”), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease (“SCD”) and other hemoglobinopathies.
-
New Study: Over-the-Counter (OTC) Products Used by Millions of Americans Saves Healthcare System Billions Annually
3/18/2019
Today, the Consumer Healthcare Products Association (CHPA) released a new study, “Value of OTC Medicines to the U.S. Healthcare System,” that found, on average, each dollar spent on over-the-counter (OTC) medicines saves the U.S. healthcare system approximately $7.20, totaling nearly $146 billion in annual savings.